全文获取类型
收费全文 | 539篇 |
免费 | 44篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 15篇 |
妇产科学 | 20篇 |
基础医学 | 73篇 |
口腔科学 | 16篇 |
临床医学 | 39篇 |
内科学 | 62篇 |
皮肤病学 | 1篇 |
神经病学 | 22篇 |
特种医学 | 40篇 |
外国民族医学 | 1篇 |
外科学 | 176篇 |
综合类 | 10篇 |
预防医学 | 21篇 |
眼科学 | 7篇 |
药学 | 52篇 |
中国医学 | 2篇 |
肿瘤学 | 35篇 |
出版年
2023年 | 3篇 |
2022年 | 4篇 |
2021年 | 13篇 |
2020年 | 9篇 |
2019年 | 15篇 |
2018年 | 16篇 |
2017年 | 16篇 |
2016年 | 10篇 |
2015年 | 9篇 |
2014年 | 20篇 |
2013年 | 29篇 |
2012年 | 39篇 |
2011年 | 33篇 |
2010年 | 14篇 |
2009年 | 20篇 |
2008年 | 15篇 |
2007年 | 20篇 |
2006年 | 13篇 |
2005年 | 22篇 |
2004年 | 14篇 |
2003年 | 20篇 |
2002年 | 15篇 |
2001年 | 13篇 |
2000年 | 15篇 |
1999年 | 8篇 |
1998年 | 12篇 |
1997年 | 6篇 |
1996年 | 8篇 |
1995年 | 9篇 |
1994年 | 7篇 |
1993年 | 5篇 |
1992年 | 4篇 |
1991年 | 8篇 |
1990年 | 12篇 |
1989年 | 10篇 |
1988年 | 19篇 |
1987年 | 14篇 |
1986年 | 22篇 |
1985年 | 10篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1981年 | 7篇 |
1980年 | 2篇 |
1978年 | 3篇 |
1976年 | 2篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1969年 | 2篇 |
1966年 | 3篇 |
1965年 | 2篇 |
排序方式: 共有604条查询结果,搜索用时 31 毫秒
31.
Naguib M 《British journal of anaesthesia》2002,88(4):606-7; author reply 607
32.
33.
Ashour OM Naguib FN Goudgaon NM Schinazi RF el Kouni MH 《Cancer chemotherapy and pharmacology》2000,46(3):235-240
Purpose: The purpose of this investigation was to study the effects of combining oral 5-(phenylselenenyl)acyclouridine (PSAU) with
2′,3′,5′-tri-O-acetyluridine (TAU) on the levels of plasma uridine in mice. PSAU is a new lipophilic and potent inhibitor of uridine phosphorylase
(UrdPase, EC 2.4.2.3), the enzyme responsible for uridine catabolism. PSAU has 100% oral bioavailability and is a powerful
enhancer of the bioavailability of oral uridine. TAU is a prodrug of uridine and a far superior source of uridine than uridine
itself. Methods: Oral TAU was administered to mice alone or with PSAU. The plasma levels of uridine and its catabolites as well as PSAU were
measured using HPLC and pharmacokinetic analysis was performed. Results: Oral administration of 2000 mg/kg TAU increased plasma uridine by over 250-fold with an area under the curve (AUC) of 754 μmol · h/l.
Coadministration of PSAU at 30 and 120 mg/kg with TAU further improved the bioavailability of plasma uridine resulting from
the administration of TAU alone by 1.7- and 3.9-fold, respectively, and reduced the Cmax and AUC of plasma uracil. Conclusion: The exceptional effectiveness of PSAU plus TAU in elevating and sustaining a high plasma uridine concentration could be
useful in the management of medical disorders that are remedied by administration of uridine, as well as the rescue or protection
from host toxicities of various chemotherapeutic pyrimidine analogues.
Received: 10 November 1999 / Accepted: 14 March 2000 相似文献
34.
Ashour OM Al Safarjalani ON Naguib FN Goudgaon NM Schinazi RF el Kouni MH 《Cancer chemotherapy and pharmacology》2000,45(5):351-361
PURPOSE: The purpose of this investigation was to evaluate the efficacy of oral 5-(phenylselenenyl)-acyclouridine (PSAU) in increasing endogenous plasma uridine concentration as well as its ability to improve the bioavailability of oral uridine. PSAU is a new potent and specific inhibitor of uridine phosphorylase (Urd-Pase, EC 2.4.2.3), the enzyme responsible for uridine catabolism. This compound was designed as a lipophilic inhibitor in order to facilitate its access to the liver and intestine, the main organs involved in uridine catabolism. METHODS: Oral PSAU was administered orally to mice alone or with uridine. The plasma levels of PSAU as well as uridine and its catabolites were measured using high-performance liquid chromatography and pharmacokinetic analysis was performed. RESULTS: PSAU has an oral bioavailability of 100% and no PSAU metabolites were detected. PSAU has no apparent toxicity at high doses. Oral administration of PSAU at 30 and 120 mg/kg increased baseline concentration of endogenous plasma uridine (2.6 +/- 0.7 microM) by 3.2- and 8.7-fold, respectively, and remained three- and six-fold higher, respectively, than the controls for over 8 h. PSAU, however, did not alter the concentration of endogenous plasma uracil. Co-administration of PSAU with uridine elevated the concentration of plasma uridine over that resulting from the administration of either alone, and reduced the peak plasma concentration (C(max)) and area under the curve (AUC) of plasma uracil. Co-administration of PSAU at 30 mg/kg and 120 mg/kg improved the low bioavailability of oral uridine (7.7%) administered at 1,320 mg/kg by 4.8- and 4.2-fold, respectively, and reduced the AUC of plasma uracil from 1,421 to 787 micromol/h x l and 273 micromol/h x l, respectively. Similar results were observed when PSAU was co-administered with lower doses of uridine. Oral PSAU at 30 mg/kg and 120 mg/kg improved the bioavailability of oral 330 mg/kg uridine by 5.2- and 8.9-fold, and that of oral 660 mg/kg uridine by 6.4- and 9.0-fold, respectively. However, the reduction in the AUC values of plasma uracil was less dramatic than that seen when the high dose of 1,320 mg/kg uridine was used. CONCLUSION: The effectiveness of the PSAU plus uridine combination in elevating and sustaining high plasma uridine concentration may be useful to rescue or protect from host toxicity of various chemotherapeutic pyrimidine analogs as well as in the management of medical disorders that are remedied by administration of uridine. 相似文献
35.
M Naguib S M Al-Rajeh M Abdulatif W A Ababtin 《Middle East journal of anesthesiology》1988,9(5):429-434
The anesthetic management of a 17-year-old female with von Recklinghausen's disease (multiple neurofibromatosis) is described. Multiple neurofibromatosis is a rare syndrome characterized by abnormal cutaneous pigmentation and numerous skin tumors. In addition to the usual stigmata of the syndrome, patients with neurofibromatosis have been reported to be either sensitive or resistant to succinylcholine. Further, all reports indicate that response to nondepolarizing muscle relaxants is exaggerated. In this patient, the nerve conduction studies were within limit of normal values. During surgery, neuromuscular function was monitored throughout using the train-of-four mechanical twitch response. The response of this patient to succinylcholine was normal and the response to atracurium was slightly prolonged. It is concluded that atracurium offers advantages over the other nondepolarizing muscle relaxants in patients with von Recklinghausen's disease. 相似文献
36.
37.
38.
Redundant nerve roots of the cauda equina 总被引:1,自引:0,他引:1
39.
Naguib MB 《The Journal of laryngology and otology》2005,119(5):381-384
In this experimental study, we attempted to perform selective deafferentation of the posterior semicircular canal ampulla of guinea pigs using carbon dioxide laser beam. The results of this study document the efficacy of this procedure in achieving deafferentation of the posterior semicircular canal safely with regards to the other semicircular canals, the otolithic organ and the organ of hearing. Moreover, the procedure is performed with relative ease compared with other procedures previously described for selective deafferentation of the posterior semicircular canal. The clinical application of such a procedure for the treatment of intractable benign paroxysmal positional vertigo in humans is suggested. 相似文献
40.
Rapid progress in understanding the molecular basis of neurodegeneration has been tightly linked with recent discoveries in the field of programmed cell death (PCD). Analysis of PCD in neuronal demise has led to identification of several associated phenomena, such as re-initiation of the cell cycle and the key role of oxidative stress, although putative causal relationships between these events are still debatable. These issues are reviewed here in the context of acute and chronic neurodegenerative processes. In addition, newly emerging concepts concerning cell-cycle re-initiation are discussed in terms of their potential impact on the development of more effective therapeutic strategies. 相似文献